ADCs in Ovarian Cancer: From Platinum Resistant Disease Towards Earlier Lines & Combinations
10:00 am - Monday 8th March 2027
- What does the phase II/III dataset tell us about ADC efficacy and tolerability in ovarian cancer?
- Moving into earlier lines and combinations: Implications for trial design and patient selection
- Delving into site-level lessons on recruitment, biomarker screening and safety management
